One Health provides FidoCure®, a human-grade precision medicine platform that enables pet parents and veterinarians to access genetic-driven oncology care for dogs. FidoCure uses next-generation sequencing at a CLIA-certified lab to identify genetic mutations, produces precision medicine reports with clear therapeutic recommendations, and facilitates access to individualized, targeted treatments. The service is available in all U.S. states through more than 200 participating veterinarians and has enrolled over 1,000 dogs. Led by co-founder and CEO Christina Lopes, the company plans to accelerate expansion of its flagship product using the newly raised funds. The article frames the company as focused on translating human-grade science into veterinary oncology to broaden treatment access for canine patients. One Health Company markets FidoCure, a product that uses next-generation gene sequencing to identify the genetic mutations driving an individual dog’s cancer and then provides recommendations and an action plan. The service outlines therapeutic implications and targeted treatments, referencing FDA-approved human drugs with data relevant to dogs. The company says it has worked with pharmaceutical partners and compounding pharmacies to close the information gap and translate human drug data to canine care. One Health is "100 percent partnered with veterinarians," charging veterinarians directly while vets continue to see patients in person. Founder and CEO Christina Lopes frames the company’s purpose as actionability—moving from testing to clear treatment steps. The startup positions FidoCure as a lower-cost alternative to average canine cancer care (average cost cited at $6,700) by designing pricing to cost less than typical care even with markup. The One Health Company operates as a contract research organization that recruits dogs and cats with naturally occurring diseases that mirror human conditions to run clinical trials without inducing illness. It uses software to scrape trial-site databases and maintains a proprietary database of roughly 450,000 potential pets for recruitment, and families collect behavioral and outcome data via smartphone using the company’s clinical-trial management software. Pets remain with their families, diseases are never induced, and euthanasia is explicitly not considered in trials; the company positions this as a more ethical and predictive alternative to traditional animal testing. The startup has established partnerships with more than 35 trial sites in the U.S. and abroad, including France, Belgium, and Brazil, and is currently running two live trials on different diseases. Founders Christina Lopes (CEO) and Benjamin Lewis (co-founder and COO) emphasize use cases in combination therapies and immunotherapy where naturally immunocompetent pets provide more predictive data than lab animals. Financially, the company has raised more than $750,000 to date and received $50,000 through participation in the University City Science Center Digital Health Accelerator. The company has also set up contracts with a top gene therapy lab, one of the five largest pharmaceutical companies, and a top-five medical device company.

Total raised

$16M

Funding rounds

3

Latest round

Equity

Latest activity

Nov 2020